WASHINGTON (MedPage Today) — After nearly 50 years, the drug development pipeline for new tuberculosis treatments is finally opening up again, according to infectious disease specialists.
No Comments »
Filed under: General Health News
In an ambitious effort to stem the dangerous tide of tuberculosis (TB) and deadly drug-resistant TB around the world, TB Alliance today announced that it has launched a first-of-its-kind clinical trial to test a novel drug combination – in both patients who have TB and those who have multidrug-resistant TB (MDR-TB).
No Comments »
Filed under: Pharmacy News
“After seven years of research, the world’s largest study of preventative tuberculosis (TB) therapy has found that untargeted, community-wide distribution of TB prevention drugs did not improve TB control in South African gold mines,” PlusNews reports.
No Comments »
Filed under: Pharmacy News
Aeras announces today that the National Institute of Allergy and Infectious Diseases (NIAID), part of the United States National Institutes of Health (NIH), has joined as a partner for a Phase II proof-of-concept clinical trial of a tuberculosis vaccine candidate jointly developed by Aeras and Dutch biopharmaceutical company Crucell.
No Comments »
Filed under: Pharmacy News
“For the first time in India, 12 people have been detected with totally drug-resistant lung tuberculosis (TDR-TB), a condition in which patients do not respond to any TB medication” and for which the mortality rate is 100 percent, the Hindustan Times reports.
No Comments »
Filed under: Pharmacy News
The incidence of tuberculosis (TB) diagnosis is significantly increased in mothers postpartum, suggesting a potential new population to target for screening, according to a new UK-wide cohort study…
No Comments »
Filed under: Women's Health
Research, led by Timothy Sterling, M.D., professor of Medicine at Vanderbilt University Medical Center, has led to an important change in CDC recommendations in the regimen for prevention of the centuries-old scourge, tuberculosis (TB).
No Comments »
Filed under: Pharmacy News
(MedPage Today) — A combination treatment for latent tuberculosis, delivered over three months, works as well as standard nine-month therapy with isoniazid, researchers reported.
No Comments »
Filed under: General Health News
In research at SRI International, scientists evaluating new drug targets against tuberculosis (TB) recently validated the preclinical effectiveness of a target that could rapidly eliminate infections and potentially shorten treatment time. The new drug target is a protein called DNA gyrase B, found in bacteria that cause TB infections.
No Comments »
Filed under: Pharmacy News
The TB Alliance announces the launch of a collaboration with the National Institute of Allergy and Infectious Diseases’ (NIAID) AIDS Clinical Trial Group (ACTG) to conduct and help complete a Phase III clinical trial testing potentially faster-acting tuberculosis (TB) treatments.
No Comments »
Filed under: Pharmacy News
